Pharmaceutical companies are investing heavily in dual- and triple-action therapies that combine GLP-1 receptor activity with GIP and glucagon receptor modulation to achieve superior weight-loss and metabolic outcomes
Withdrawal from opioids can make a person feel sleepy, but they may also have difficulty getting good quality sleep
Mechanistically, semaglutide glucose-dependently potentiates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain via circumventricular organs
requires screening and monitoring Lifestyle + medical coaching What it is: Nutrition, movement, sleep, and behavior supports Primary effect: Foundation (improves consistency and maintenance) Evidence for weight loss: Strong What to know: Makes every other option work better and supports long-term results Important safety note on online GLP-1s: If youre considering semaglutide/tirzepatide, avoid sketchy sources and dosing confusion
A 30-min permeability test for SF and EBA markers performed after the 24-h nanocarrier permeability assays confirmed that the integrity of the BBB models was preserved and the nanocarriers had no barrier damaging effect (Table S2)
Managing these medicines requires careful planning and individualised treatment, guided by a healthcare professional
